Compare Charles River Laboratories Intl. Inc (CRL) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs KeyCorp — how do they compare? Charles River Laboratories Intl. Inc trades at $228.98 (market cap $11.14B), while KeyCorp trades at $23.23 (market cap $25.15B). The key difference: KeyCorp is far larger — about 2.3× Charles River Laboratories Intl. Inc's market cap, and KeyCorp pays a 3.52% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | KEY | |
|---|---|---|
Market Cap | $11.14B | $25.15B |
Sector | Health | Financials |
52-Week High | $233.60 | $23.43 |
52-Week Low | $145.57 | $16.78 |
Enterprise Value | $14.00B | — |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
KeyCorp (KEY) trades at $23.22, down 0.34% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamental recovery with Q1 2026 EPS beating expectations at $0.44 and a net income margin of 26.05% for 2025. Analyst consensus is heavily bullish with a $29.32 price target, and recent news highlights partnerships and a new $3 billion buyback program.
The outlook for KEY is positive, driven by earnings beats, robust capital returns, and improving profitability. Risks include volatile cash flows and macroeconomic sensitivity, but institutional support and a low P/E of 14.25 suggest undervaluation, offering potential upside for investors seeking regional bank exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
